OncoVista Innovative Therapies, Inc.

OVITOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$2356

P/E Ratio—

52W High$0.0004

52W Low$0.0001

Avg Volume5K

Open$0.00

Beta-45.23

Free Cash Flow Financials Revenue

OncoVista Innovative Therapies, Inc. (OVIT) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

OVIT · free cash flow · updated Jun 9, 2026

Core FCF metrics

OVIT · FCF · TTM · margin & CAGR

Free cash flow was −$232,384 for FY2014 (fiscal year ending 2014-12-31), up 50.2% year-over-year

FY2014 Free Cash Flow−$232,384▲ +50.2% YoY

Trailing 12M (TTM)−$264,361trailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

OVIT · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2014Latest−$232,384(0M)−$232,384▲ +50.2%—

FY2013−$466,789(0M)−$466,789▲ +70.0%—

FY2012−$1.6M(0M)−$1.6M▲ +3.6%—

FY2011−$1.6M(0M)−$1.6M▼ 190.4%—

FY2010−$554,955(0M)−$554,955▲ +39.1%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

OVIT · P/FCF · FCF yield · FCF per share

OncoVista Innovative Therapies, Inc. (OVIT) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2014 · 2014-12-31

Cash flow statement summary

OVIT · cash flow statement · operating / investing / financing

For FY2014, OncoVista Innovative Therapies, Inc. generated −$0.2M in operating cash flow and spent 0M in capital expenditures, yielding −$0.2M in free cash flow.

Operating Activities

−$0.2M

Cash from core business operations

2014-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2014-12-31

Financing Activities

+$0.2M

Buybacks, dividends & debt

2014-12-31

FCF FormulaOperating CF (−$0.2M) − |CapEx| (0M) = FCF (−$0.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

OVIT vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

OncoVista Innovative Therapies, Inc.YOU

OVIT

−$232,384+50.2%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

OncoVista Innovative Therapies, Inc. (OVIT) reported free cash flow of −$232,384 for FY2014 (fiscal year ending 2014-12-31), up 50.2% year-over-year.

OncoVista Innovative Therapies, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 11 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

OVIT free cash flow · 8 questions

OncoVista Innovative Therapies, Inc. free cash flow was −$232,384 for FY2014, up 50.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$264,361.

OVIT free cash flowOVIT FCFOVIT FCF 2014OVIT free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · OncoVista Innovative Therapies, Inc. · OncoVista Innovative Therapies, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026